FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285903> ?p ?o ?g. }

• W4379285903 endingPage "596" @default.
• W4379285903 startingPage "596" @default.
• W4379285903 abstract "596 Background: Early stage HER2 positive breast cancer (BC) patients (pts) are commonly treated with neoadjuvant HER2-targeted therapy. Optimizing neoadjuvant therapy by improving efficacy while reducing toxicity is a critical unmet need. IT DC 1 therapy combined with an IgG1 antibody mediating ADCC drives strong anti-HER-2 CD4 Th1 responses and complete tumor regression in preclinical models. We initiated a phase I/II neoadjuvant study to explore the efficacy and immune stimulation effects of an initial 6 weeks of immunotherapy phase (IP) using IT DC1 vaccine plus trastuzumab (H) and pertuzumab (P) (as source of IgG1) followed by 12 weeks of paclitaxel (T) and HP. Methods: Early stage HER2+ BC pts with tumor ≥ 1cm were eligible. Treatment included IT DC1 weekly x6 followed by paclitaxel 80 mg/m 2 IV weekly x 12. Trastuzumab IV every (q) 3 weeks (8 mg/kg loading dose, then 6 mg/m 2 ) and pertuzumab IV q 3 weeks (840 mg loading dose, then 420 mg) x 6 cycles starting from day 1. Two dose levels (DL) of IT DC1 (DL1 = 50 million and DL2 = 100 million cells) were evaluated including 6 pts in each DL. Once the optimal DL is determined based on toxicities, additional 22 patients will be enrolled in expansion phase 2 trial. The primary end point of the phase 1 is the safety, immune responses (measured by ELISPOT). MRI breast was performed at the baseline, post-immunotherapy and post-chemotherapy. Here we are reporting the safety and immune correlates in phase 1 study. Results: Twelve pts were enrolled between 10/2021 and 10/2022. Median age was 57 (range 34-74). Nine pts had hormone receptor positive disease with clinical stage I/II/III (5/5/2) and 4 pts had node positive disease. All pts completed IP and 10 patients completed THP chemotherapy as of 2/1/2023. Radiologic response per MRI breast on pre and post-IP showed 6 partial response, 3 complete response and 3 stable disease. Nine pts underwent surgery and 6 out of 9 pts had pCR (RCB 0). The most frequently observed toxicities were chills (50%), diarrhea (42%), nausea (42%), fatigue (42%), and headache (42%). ELISPOT demonstrated a significant decrease of HER2- specific T cell response following 6 weeks of DC1 IT injections in DL2 compared to DL1. Conclusions: The addition of IT DC1/HP to neoadjuvant chemotherapy was well tolerated with manageable toxicities. The 100 million DC1 led to a significant decrease in peripherally circulating anti-HER2 T cell response at week 6 following IP and improved radiologic tumor responses which correlates with a higher likelihood of pCR. Data from another IT DC1 trial suggests decreased circulating HER2 responsive T cells are due to increased trafficking of reactive T cells out of circulation into the tumor possibly leading to an enhanced anti-tumor effect. Updated results including correlative biomarkers will be presented at the meeting. Clinical trial information: NCT05325632 ." @default.
• W4379285903 created "2023-06-05" @default.
• W4379285903 creator A5006005284 @default.
• W4379285903 creator A5006750441 @default.
• W4379285903 creator A5011430743 @default.
• W4379285903 creator A5014744153 @default.
• W4379285903 creator A5016883669 @default.
• W4379285903 creator A5023384641 @default.
• W4379285903 creator A5024796779 @default.
• W4379285903 creator A5026765782 @default.
• W4379285903 creator A5028445191 @default.
• W4379285903 creator A5028767875 @default.
• W4379285903 creator A5036240983 @default.
• W4379285903 creator A5039643514 @default.
• W4379285903 creator A5046645773 @default.
• W4379285903 creator A5051916408 @default.
• W4379285903 creator A5059240684 @default.
• W4379285903 creator A5060576547 @default.
• W4379285903 creator A5067249314 @default.
• W4379285903 creator A5075333609 @default.
• W4379285903 creator A5085929131 @default.
• W4379285903 creator A5090789911 @default.
• W4379285903 date "2023-06-01" @default.
• W4379285903 modified "2023-09-26" @default.
• W4379285903 title "Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial." @default.
• W4379285903 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.596" @default.
• W4379285903 hasPublicationYear "2023" @default.
• W4379285903 type Work @default.
• W4379285903 citedByCount "0" @default.
• W4379285903 crossrefType "journal-article" @default.
• W4379285903 hasAuthorship W4379285903A5006005284 @default.
• W4379285903 hasAuthorship W4379285903A5006750441 @default.
• W4379285903 hasAuthorship W4379285903A5011430743 @default.
• W4379285903 hasAuthorship W4379285903A5014744153 @default.
• W4379285903 hasAuthorship W4379285903A5016883669 @default.
• W4379285903 hasAuthorship W4379285903A5023384641 @default.
• W4379285903 hasAuthorship W4379285903A5024796779 @default.
• W4379285903 hasAuthorship W4379285903A5026765782 @default.
• W4379285903 hasAuthorship W4379285903A5028445191 @default.
• W4379285903 hasAuthorship W4379285903A5028767875 @default.
• W4379285903 hasAuthorship W4379285903A5036240983 @default.
• W4379285903 hasAuthorship W4379285903A5039643514 @default.
• W4379285903 hasAuthorship W4379285903A5046645773 @default.
• W4379285903 hasAuthorship W4379285903A5051916408 @default.
• W4379285903 hasAuthorship W4379285903A5059240684 @default.
• W4379285903 hasAuthorship W4379285903A5060576547 @default.
• W4379285903 hasAuthorship W4379285903A5067249314 @default.
• W4379285903 hasAuthorship W4379285903A5075333609 @default.
• W4379285903 hasAuthorship W4379285903A5085929131 @default.
• W4379285903 hasAuthorship W4379285903A5090789911 @default.
• W4379285903 hasConcept C121608353 @default.
• W4379285903 hasConcept C126322002 @default.
• W4379285903 hasConcept C126894567 @default.
• W4379285903 hasConcept C143998085 @default.
• W4379285903 hasConcept C203014093 @default.
• W4379285903 hasConcept C203092338 @default.
• W4379285903 hasConcept C2776090121 @default.
• W4379285903 hasConcept C2776694085 @default.
• W4379285903 hasConcept C2777292972 @default.
• W4379285903 hasConcept C2778292576 @default.
• W4379285903 hasConcept C2779053233 @default.
• W4379285903 hasConcept C2779786085 @default.
• W4379285903 hasConcept C2781164504 @default.
• W4379285903 hasConcept C31760486 @default.
• W4379285903 hasConcept C530470458 @default.
• W4379285903 hasConcept C535046627 @default.
• W4379285903 hasConcept C71924100 @default.
• W4379285903 hasConcept C8891405 @default.
• W4379285903 hasConceptScore W4379285903C121608353 @default.
• W4379285903 hasConceptScore W4379285903C126322002 @default.
• W4379285903 hasConceptScore W4379285903C126894567 @default.
• W4379285903 hasConceptScore W4379285903C143998085 @default.
• W4379285903 hasConceptScore W4379285903C203014093 @default.
• W4379285903 hasConceptScore W4379285903C203092338 @default.
• W4379285903 hasConceptScore W4379285903C2776090121 @default.
• W4379285903 hasConceptScore W4379285903C2776694085 @default.
• W4379285903 hasConceptScore W4379285903C2777292972 @default.
• W4379285903 hasConceptScore W4379285903C2778292576 @default.
• W4379285903 hasConceptScore W4379285903C2779053233 @default.
• W4379285903 hasConceptScore W4379285903C2779786085 @default.
• W4379285903 hasConceptScore W4379285903C2781164504 @default.
• W4379285903 hasConceptScore W4379285903C31760486 @default.
• W4379285903 hasConceptScore W4379285903C530470458 @default.
• W4379285903 hasConceptScore W4379285903C535046627 @default.
• W4379285903 hasConceptScore W4379285903C71924100 @default.
• W4379285903 hasConceptScore W4379285903C8891405 @default.
• W4379285903 hasIssue "16_suppl" @default.
• W4379285903 hasLocation W43792859031 @default.
• W4379285903 hasOpenAccess W4379285903 @default.
• W4379285903 hasPrimaryLocation W43792859031 @default.
• W4379285903 hasRelatedWork W2066747782 @default.
• W4379285903 hasRelatedWork W2328377843 @default.
• W4379285903 hasRelatedWork W2560406314 @default.
• W4379285903 hasRelatedWork W2595594315 @default.
• W4379285903 hasRelatedWork W2751857407 @default.
• W4379285903 hasRelatedWork W2760874931 @default.
• W4379285903 hasRelatedWork W2921988831 @default.
• W4379285903 hasRelatedWork W4229446258 @default.

• next